Accepted for Publication: July 26, 2013.
Published Online: November 4, 2013. doi:10.1001/jamainternmed.2013.11950.
Study concept and design: Mason.
Acquisition of data: Quello, Shadan, Kyle, Begovic.
Analysis and interpretation of data: Mason, Goodell.
Drafting of the manuscript: Mason.
Critical revision of the manuscript for important intellectual content: Mason, Quello, Goodell, Shadan, Kyle, Begovic.
Statistical analysis: Goodell.
Obtained funding: Mason.
Study supervision: Mason, Quello, Shadan, Kyle, Begovic.
Conflict of Interest Disclosures: Dr Mason has served as a consultant for Eli Lilly USA LLC and Johnson & Johnson Pharmaceutical Research & Development LLC; has served as a scientific advisory board member for Lohocla Research Corp; has served as a scientific advisory board member for and has had equity interest in Addex Pharmaceuticals and in Arkeo Pharmaceuticals Inc; has served as a speaker for Merck KGaA; and has received study drug for a National Institute on Alcohol Abuse and Alcoholism (NIAAA)-funded human laboratory study and travel support for an investigators’ meeting from Corcept Therapeutics Inc. No other conflicts of interest are reported.
Funding/Support: This project was funded by NIAAA grant No. R37AA014028. Gabapentin and matched placebo were provided by Pfizer Pharmaceuticals Inc.
Role of the Sponsor: The NIAAA and Pfizer had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Additional Contributors: Eli Miller, MD, a psychiatrist in private practice in La Jolla, California, generously provided unpaid consultation during the formative stage of this project. Jamie Kissee, MA, contributed assistance in preparing the manuscript with compensation provided as part of her employment at The Scripps Research Institute. Gabapentin concentration in plasma was assayed in the laboratory of Thomas Cooper, MA, at The Nathan Kline Institute, Orangeburg, New York.